JP5651275B2 - テノホビルアラフェナミドヘミフマレート - Google Patents

テノホビルアラフェナミドヘミフマレート Download PDF

Info

Publication number
JP5651275B2
JP5651275B2 JP2014526164A JP2014526164A JP5651275B2 JP 5651275 B2 JP5651275 B2 JP 5651275B2 JP 2014526164 A JP2014526164 A JP 2014526164A JP 2014526164 A JP2014526164 A JP 2014526164A JP 5651275 B2 JP5651275 B2 JP 5651275B2
Authority
JP
Japan
Prior art keywords
hemifumarate
composition
tenofovir arafenamide
hiv
tenofovir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014526164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528924A (ja
Inventor
ダザン リュー
ダザン リュー
ビン シー
ビン シー
ファン ワン
ファン ワン
リチャード フン チウ ユー
リチャード フン チウ ユー
Original Assignee
ギリアード サイエンシス インコーポレーテッド
ギリアード サイエンシス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5651275(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ギリアード サイエンシス インコーポレーテッド, ギリアード サイエンシス インコーポレーテッド filed Critical ギリアード サイエンシス インコーポレーテッド
Publication of JP2014528924A publication Critical patent/JP2014528924A/ja
Application granted granted Critical
Publication of JP5651275B2 publication Critical patent/JP5651275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2014526164A 2011-08-16 2012-08-15 テノホビルアラフェナミドヘミフマレート Active JP5651275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524224P 2011-08-16 2011-08-16
US61/524,224 2011-08-16
PCT/US2012/050920 WO2013025788A1 (en) 2011-08-16 2012-08-15 Tenofovir alafenamide hemifumarate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014231819A Division JP5956537B2 (ja) 2011-08-16 2014-11-14 テノホビルアラフェナミドヘミフマレート

Publications (2)

Publication Number Publication Date
JP2014528924A JP2014528924A (ja) 2014-10-30
JP5651275B2 true JP5651275B2 (ja) 2015-01-07

Family

ID=46785793

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014526164A Active JP5651275B2 (ja) 2011-08-16 2012-08-15 テノホビルアラフェナミドヘミフマレート
JP2014231819A Active JP5956537B2 (ja) 2011-08-16 2014-11-14 テノホビルアラフェナミドヘミフマレート
JP2016120153A Active JP6280162B2 (ja) 2011-08-16 2016-06-16 テノホビルアラフェナミドヘミフマレート
JP2018006107A Withdrawn JP2018065870A (ja) 2011-08-16 2018-01-18 テノホビルアラフェナミドヘミフマレート
JP2019210196A Pending JP2020040972A (ja) 2011-08-16 2019-11-21 テノホビルアラフェナミドヘミフマレート

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014231819A Active JP5956537B2 (ja) 2011-08-16 2014-11-14 テノホビルアラフェナミドヘミフマレート
JP2016120153A Active JP6280162B2 (ja) 2011-08-16 2016-06-16 テノホビルアラフェナミドヘミフマレート
JP2018006107A Withdrawn JP2018065870A (ja) 2011-08-16 2018-01-18 テノホビルアラフェナミドヘミフマレート
JP2019210196A Pending JP2020040972A (ja) 2011-08-16 2019-11-21 テノホビルアラフェナミドヘミフマレート

Country Status (41)

Country Link
US (2) US8754065B2 (enExample)
EP (3) EP3831832A1 (enExample)
JP (5) JP5651275B2 (enExample)
KR (1) KR101612642B1 (enExample)
CN (2) CN110343135A (enExample)
AP (1) AP3639A (enExample)
AR (1) AR087546A1 (enExample)
AU (1) AU2012296622C1 (enExample)
BR (1) BR112014003420B1 (enExample)
CA (1) CA2845553C (enExample)
CL (1) CL2014000370A1 (enExample)
CO (1) CO6880063A2 (enExample)
CR (1) CR20140072A (enExample)
CY (1) CY1118385T1 (enExample)
DK (1) DK2744810T4 (enExample)
EA (1) EA027768B1 (enExample)
EC (1) ECSP14013206A (enExample)
ES (1) ES2608871T5 (enExample)
FI (1) FI2744810T4 (enExample)
HR (1) HRP20161696T4 (enExample)
HU (1) HUE031253T2 (enExample)
IL (2) IL230949A (enExample)
IN (1) IN2014DN01012A (enExample)
LT (1) LT2744810T (enExample)
MA (1) MA35350B1 (enExample)
MD (1) MD4508C1 (enExample)
ME (1) ME02612B (enExample)
MX (1) MX336627B (enExample)
PE (1) PE20141328A1 (enExample)
PH (1) PH12014500349A1 (enExample)
PL (1) PL2744810T5 (enExample)
PT (1) PT2744810T (enExample)
RS (1) RS55353B2 (enExample)
SG (1) SG2014011548A (enExample)
SI (1) SI2744810T2 (enExample)
SM (2) SMT201600476T1 (enExample)
TW (1) TWI516499B (enExample)
UA (1) UA115311C2 (enExample)
UY (1) UY34262A (enExample)
WO (1) WO2013025788A1 (enExample)
ZA (1) ZA201400582B (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
AR088109A1 (es) 2014-04-11 2014-05-07 Gilead Sciences Inc Metodo para preparar analogos nucleotidicos antivirales
MD20140091A2 (ro) * 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
TWI660965B (zh) * 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
CN108191913A (zh) * 2014-11-12 2018-06-22 四川海思科制药有限公司 一种替诺福韦艾拉酚胺晶型a及其制备方法
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016108205A1 (en) * 2015-01-03 2016-07-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
CN105669751B (zh) * 2015-03-05 2018-09-21 洛阳聚慧医药科技有限公司 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
JP2018524308A (ja) * 2015-06-17 2018-08-30 ギリアード サイエンシーズ， インコーポレイテッド テノホビルアラフェナミドの共結晶、塩および結晶形態
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
MX386992B (es) 2015-08-10 2025-03-19 Merck Sharp & Dohme Llc Compuestos antivirales de fosfodiamida de éster de beta-aminoácido.
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
CN106699812A (zh) * 2015-11-12 2017-05-24 江苏豪森药业集团有限公司 替诺福韦前药的制备和纯化方法
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en) * 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
PT3411378T (pt) 2016-02-02 2020-07-28 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017203395A1 (en) * 2016-05-21 2017-11-30 Shilpa Medicare Limited Crystalline forms of tenofovir alafenamide hemi fumarate
WO2017211325A1 (zh) * 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
SI3347352T1 (sl) 2016-08-19 2019-08-30 Gilead Sciences, Inc. Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
EP3503895B1 (en) 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN107793451A (zh) * 2016-08-30 2018-03-13 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
CN113072583A (zh) * 2016-11-28 2021-07-06 正大天晴药业集团股份有限公司 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
MA47094A (fr) 2016-12-22 2021-05-26 Idenix Pharmaceuticals Llc Promédicaments d'ester aliphatique antiviral de ténofovir
WO2018113652A1 (zh) 2016-12-23 2018-06-28 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
TWI868958B (zh) * 2017-01-31 2025-01-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN107445994A (zh) * 2017-05-31 2017-12-08 北京阜康仁生物制药科技有限公司 替诺福韦艾拉酚胺半富马酸盐新晶型
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法
WO2019084020A1 (en) 2017-10-24 2019-05-02 Gilead Sciences, Inc. METHODS OF TREATING PATIENTS CO-INFECTED BY A VIRUS AND TUBERCULOSIS
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
WO2019130354A1 (en) * 2017-12-30 2019-07-04 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
CN108440596B (zh) * 2018-03-22 2020-07-03 科兴生物制药股份有限公司 一种半富马酸替诺福韦艾拉酚胺的新型制备工艺
WO2019237957A1 (zh) 2018-06-12 2019-12-19 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
JP7313438B2 (ja) 2018-09-19 2023-07-24 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの予防のためのインテグラーゼ阻害剤
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110452268A (zh) * 2019-08-21 2019-11-15 天地恒一制药股份有限公司 一种丙酚替诺福韦半富马酸单晶的制备方法
TW202519228A (zh) 2019-11-26 2025-05-16 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
EP4085062A1 (en) 2020-02-20 2022-11-09 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
EP4172157B1 (en) 2020-06-25 2025-11-19 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP4660325A3 (en) 2020-11-11 2026-02-25 Gilead Sciences, Inc. Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
KR20250051732A (ko) 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
CN121358478A (zh) 2023-04-19 2026-01-16 吉利德科学公司 衣壳抑制剂的给药方案
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
AU2023460182A1 (en) 2023-07-28 2026-02-05 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025080879A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DE69129650T2 (de) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
WO1998004569A1 (en) 1996-07-26 1998-02-05 Gilead Sciences, Inc. Nucleotide analogs
CN101239989B (zh) 1996-07-26 2012-12-12 吉联亚科学股份有限公司 核苷酸类似物
PT1243590E (pt) 1997-07-25 2005-05-31 Gilead Sciences Inc Composicao de analogos nuclotidicos e metodo de sintese
OA12393A (en) 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
MY131488A (en) 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP2004288898A (ja) * 2003-03-24 2004-10-14 Canon Inc 太陽電池モジュールの製造方法
ECSP045074A (es) 2004-04-22 2004-05-28 Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih
EP1758581A1 (en) 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
PT2049506E (pt) 2006-07-07 2015-10-09 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
WO2008007392A2 (en) 2006-07-12 2008-01-17 Matrix Laboratories Limited Process for the preparation of tenofovir
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
SG173544A1 (en) 2009-02-06 2011-09-29 Gilead Sciences Inc Tablets for combination therapy
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
AR088109A1 (es) 2014-04-11 2014-05-07 Gilead Sciences Inc Metodo para preparar analogos nucleotidicos antivirales
MD20140091A2 (ro) 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale

Also Published As

Publication number Publication date
US20130065856A1 (en) 2013-03-14
JP5956537B2 (ja) 2016-07-27
AU2012296622B2 (en) 2014-09-11
UY34262A (es) 2013-04-05
AU2012296622C1 (en) 2017-02-16
DK2744810T3 (en) 2016-12-05
HRP20161696T4 (hr) 2023-10-13
AP2014007437A0 (en) 2014-02-28
CL2014000370A1 (es) 2014-09-05
SI2744810T2 (sl) 2023-11-30
RS55353B2 (sr) 2023-11-30
NZ620421A (en) 2015-05-29
EP2744810B2 (en) 2023-09-13
ECSP14013206A (es) 2014-03-31
TWI516499B (zh) 2016-01-11
SMT201600476B (it) 2017-03-08
DK2744810T4 (da) 2023-11-20
ES2608871T5 (es) 2024-04-04
CO6880063A2 (es) 2014-02-28
RS55353B1 (sr) 2017-03-31
KR101612642B1 (ko) 2016-04-14
MD4508C1 (ro) 2018-03-31
CA2845553C (en) 2019-05-28
MA35350B1 (fr) 2014-08-01
ZA201400582B (en) 2017-11-29
AP3639A (en) 2016-03-13
PH12014500349A1 (en) 2016-04-06
AR087546A1 (es) 2014-04-03
EP2744810B1 (en) 2016-10-05
FI2744810T4 (fi) 2023-11-22
US9296769B2 (en) 2016-03-29
EA201490208A1 (ru) 2014-06-30
HUE031253T2 (en) 2017-07-28
TW201321396A (zh) 2013-06-01
JP2014528924A (ja) 2014-10-30
BR112014003420B1 (pt) 2021-07-20
AU2012296622A1 (en) 2013-05-09
PL2744810T5 (pl) 2024-02-05
LT2744810T (lt) 2016-11-25
CR20140072A (es) 2014-06-19
CN103732594A (zh) 2014-04-16
JP2015038149A (ja) 2015-02-26
IN2014DN01012A (enExample) 2015-05-15
IL230949A0 (en) 2014-03-31
CY1118385T1 (el) 2017-06-28
KR20140054068A (ko) 2014-05-08
HRP20161696T1 (hr) 2017-02-24
JP2018065870A (ja) 2018-04-26
UA115311C2 (uk) 2017-10-25
EA027768B1 (ru) 2017-08-31
US8754065B2 (en) 2014-06-17
SMT201600476T1 (it) 2017-03-08
EP3831832A1 (en) 2021-06-09
CA2845553A1 (en) 2013-02-21
HK1199026A1 (en) 2015-06-19
WO2013025788A1 (en) 2013-02-21
EP3070088A1 (en) 2016-09-21
IL230949A (en) 2015-09-24
MX2014001549A (es) 2014-02-27
SI2744810T1 (sl) 2017-01-31
JP2020040972A (ja) 2020-03-19
IL240649A0 (en) 2015-09-24
JP6280162B2 (ja) 2018-02-14
CN110343135A (zh) 2019-10-18
MD20140011A2 (en) 2014-05-31
BR112014003420A2 (pt) 2017-03-01
SG2014011548A (en) 2014-09-26
ME02612B (me) 2017-06-20
PL2744810T3 (pl) 2017-04-28
US20140187773A1 (en) 2014-07-03
PT2744810T (pt) 2016-11-04
ES2608871T3 (es) 2017-04-17
MX336627B (es) 2016-01-26
PE20141328A1 (es) 2014-10-04
JP2016169228A (ja) 2016-09-23
MD4508B1 (ro) 2017-08-31
EP2744810A1 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
JP6280162B2 (ja) テノホビルアラフェナミドヘミフマレート
UA87884C2 (uk) Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CN121358747A (zh) 核苷逆转录酶易位抑制剂的固体形式
AU2014271320B2 (en) Tenofovir alafenamide hemifumarate
HK40018109A (en) Tenofovir alafenamide hemifumarate
HK40051818A (en) Tenofovir alafenamide hemifumarate
HK1228372A1 (en) Tenofovir alafenamide hemifumarate
HK1199026B (en) Tenofovir alafenamide hemifumarate
NZ620421B2 (en) Tenofovir alafenamide hemifumarate
OA17070A (en) Tenofovir alafenamide hemifumarate.
JP6421873B2 (ja) テノホビルジソプロキシルの新規塩
JP2020509046A (ja) シクロブチル（ｓ）−２−［［［（ｒ）−２−（６−アミノプリン−９−イル）−１−メチル−エトキシ］メチル−フェノキシ−ホスホリル］アミノ］−プロパノエート、ならびにそれを生産および使用する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140527

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140527

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141114

R150 Certificate of patent or registration of utility model

Ref document number: 5651275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250